{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:37:48Z","timestamp":1793227068591,"version":"4.5.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The most prevalent cancer treatments cause cell death through DNA damage. However, DNA damage response (DDR) repair pathways, initiated by tumor cells, can withstand the effects of anticancer drugs, providing justification for combining DDR inhibitors with DNA-damaging anticancer treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cell viability assays were performed with CellTiter-Glo assay. DNA damage was evaluated using Western blotting analysis. RNA-seq and single-cell level expression were used to identify the DDR signatures. In vivo, studies were conducted in mice to determine the effect of ATris on TMZ sensitization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found a subpopulation of glioma sphere-forming cells (GSCs) with substantial synergism with temozolomide (TMZ) using a panel of 3 clinical-grade ataxia-telangiectasia- and Rad3-related kinase inhibitors (ATRis), (elimusertib, berzosertib, and ceralasertib). Interestingly, most synergistic cell lines had O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, indicating that ATRi mainly benefits tumors with no MGMT repair. Further, TMZ activated the ATR-checkpoint kinase 1 (Chk1) axis in an MGMT-dependent way. TMZ caused ATR-dependent Chk1 phosphorylation and DNA double-strand breaks as shown by increased \u03b3H2AX. Increased DNA damage and decreased Chk1 phosphorylation were observed upon the addition of ATRis to TMZ in MGMT-methylated (MGMT-) GSCs. TMZ also improved sensitivity to ATRis in vivo, as shown by increased mouse survival with the TMZ and ATRi combination treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This research provides a rationale for selectively targeting MGMT-methylated cells using ATRis and TMZ combination. Overall, we believe that MGMT methylation status in GBM could serve as a robust biomarker for patient selection for ATRi combined with TMZ.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/noajnl\/vdad165","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T19:20:59Z","timestamp":1702668059000},"source":"Crossref","is-referenced-by-count":9,"title":["MGMT function determines the differential response of ATR inhibitors with DNA-damaging agents in glioma stem cells for GBM therapy"],"prefix":"10.1093","volume":"6","author":[{"given":"Vincent W S","family":"Leong","sequence":"first","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabbir","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7070-3025","authenticated-orcid":false,"given":"Pratibha","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaofang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riya R","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay K","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3747-873X","authenticated-orcid":false,"given":"Frederick F","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred W K","family":"Yung","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5297-9220","authenticated-orcid":false,"given":"Dimpy","family":"Koul","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"issue":"2","key":"2024011116354183500_CIT0001","doi-asserted-by":"crossref","first-page":"e18591","DOI":"10.1097\/MD.0000000000018591","article-title":"Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide","volume":"99","author":"Quan","year":"2020","journal-title":"Medicine (Baltim)."},{"issue":"3","key":"2024011116354183500_CIT0002","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","article-title":"Temozolomide resistance in glioblastoma multiforme","volume":"3","author":"Lee","year":"2016","journal-title":"Genes Dis"},{"issue":"5","key":"2024011116354183500_CIT0003","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1634\/theoncologist.2016-0347","article-title":"Prolonged temozolomide maintenance therapy in newly diagnosed glioblastoma","volume":"22","author":"Skardelly","year":"2017","journal-title":"Oncologist"},{"issue":"5","key":"2024011116354183500_CIT0004","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"issue":"6","key":"2024011116354183500_CIT0005","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.3171\/2014.9.FOCUS14502","article-title":"Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles","volume":"37","author":"Barbagallo","year":"2014","journal-title":"Neurosurg Focus."},{"issue":"23","key":"2024011116354183500_CIT0006","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1200\/JCO.2008.20.7944","article-title":"Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma","volume":"27","author":"Clarke","year":"2009","journal-title":"J Clin Oncol."},{"issue":"10","key":"2024011116354183500_CIT0007","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"issue":"3","key":"2024011116354183500_CIT0008","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nrc3891","article-title":"Therapeutic opportunities within the DNA damage response","volume":"15","author":"Pearl","year":"2015","journal-title":"Nat Rev Cancer."},{"issue":"19","key":"2024011116354183500_CIT0009","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM200011093431901","article-title":"Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents","volume":"343","author":"Esteller","year":"2000","journal-title":"N Engl J Med."},{"issue":"2","key":"2024011116354183500_CIT0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/neuonc\/noy132","article-title":"MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges","volume":"21","author":"Mansouri","year":"2019","journal-title":"Neuro Oncol"},{"issue":"10","key":"2024011116354183500_CIT0011","doi-asserted-by":"crossref","first-page":"e0140131","DOI":"10.1371\/journal.pone.0140131","article-title":"Temozolomide resistance in glioblastoma cell lines: implication of MGMT, MMR, P-glycoprotein and CD133 expression","volume":"10","author":"Perazzoli","year":"2015","journal-title":"PLoS One."},{"issue":"1","key":"2024011116354183500_CIT0012","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2014.12.038","article-title":"DNA damage response--a double-edged sword in cancer prevention and cancer therapy","volume":"358","author":"Tian","year":"2015","journal-title":"Cancer Lett."},{"issue":"5","key":"2024011116354183500_CIT0013","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/neuonc\/nor010","article-title":"Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells","volume":"13","author":"Short","year":"2011","journal-title":"Neuro Oncol"},{"issue":"10","key":"2024011116354183500_CIT0014","doi-asserted-by":"crossref","first-page":"543531","DOI":"10.4061\/2010\/543531","article-title":"DNA damage induced by alkylating agents and repair pathways","volume":"2010","author":"Kondo","year":"2010","journal-title":"J Nucleic Acids"},{"issue":"6","key":"2024011116354183500_CIT0015","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1158\/1535-7163.MCT-21-0934","article-title":"A new class of selective ATM inhibitors as combination partners of DNA double-strand break inducing cancer therapies","volume":"21","author":"Zimmermann","year":"2022","journal-title":"Mol Cancer Ther."},{"issue":"9","key":"2024011116354183500_CIT0016","doi-asserted-by":"crossref","first-page":"a012716","DOI":"10.1101\/cshperspect.a012716","article-title":"DNA damage sensing by the ATM and ATR kinases","volume":"5","author":"Mar\u00e9chal","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"31","key":"2024011116354183500_CIT0017","doi-asserted-by":"crossref","first-page":"13660","DOI":"10.1073\/pnas.1007856107","article-title":"Reconstitution of RPA-covered single-stranded DNA-activated ATR-Chk1 signaling","volume":"107","author":"Choi","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"Pt 22","key":"2024011116354183500_CIT0018","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1242\/jcs.053702","article-title":"Human RPA phosphorylation by ATR stimulates DNA synthesis and prevents ssDNA accumulation during DNA-replication stress","volume":"122","author":"Vassin","year":"2009","journal-title":"J Cell Sci."},{"issue":"13","key":"2024011116354183500_CIT0019","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1128\/MCB.21.13.4129-4139.2001","article-title":"ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1","volume":"21","author":"Zhao","year":"2001","journal-title":"Mol Cell Biol."},{"issue":"7","key":"2024011116354183500_CIT0020","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1111\/cas.15845","article-title":"Emerging strategies for cancer therapy by ATR inhibitors","volume":"114","author":"Yano","year":"2023","journal-title":"Cancer Sci."},{"issue":"1","key":"2024011116354183500_CIT0021","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/stem.1528","article-title":"A high Notch pathway activation predicts response to \u03b3 secretase inhibitors in proneural subtype of glioma tumor-initiating cells","volume":"32","author":"Saito","year":"2014","journal-title":"Stem Cells."},{"issue":"18","key":"2024011116354183500_CIT0022","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Di Veroli","year":"2016","journal-title":"Bioinformatics."},{"issue":"7","key":"2024011116354183500_CIT0023","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1158\/1535-7163.MCT-15-0857","article-title":"MSK1-mediated \u03b2-catenin phosphorylation confers resistance to PI3K\/mTOR inhibitors in glioblastoma","volume":"15","author":"Wu","year":"2016","journal-title":"Mol Cancer Ther."},{"issue":"1","key":"2024011116354183500_CIT0024","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41467-022-28372-y","article-title":"Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target","volume":"13","author":"Abdelfattah","year":"2022","journal-title":"Nat Commun."},{"issue":"2","key":"2024011116354183500_CIT0025","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3171\/jns.2000.92.2.0326","article-title":"An implantable guide-screw system for brain tumor studies in small animals","volume":"92","author":"Lal","year":"2000","journal-title":"J Neurosurg."},{"issue":"2","key":"2024011116354183500_CIT0026","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1158\/1078-0432.CCR-09-1389","article-title":"Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib","volume":"16","author":"Watson","year":"2010","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2024011116354183500_CIT0027","first-page":"vdab015","article-title":"The promise of DNA damage response inhibitors for the treatment of glioblastoma","volume":"3","author":"Majd","year":"2021","journal-title":"Neurooncol Adv"},{"issue":"11","key":"2024011116354183500_CIT0028","doi-asserted-by":"crossref","first-page":"e27183","DOI":"10.1371\/journal.pone.0027183","article-title":"Rad51 and BRCA2\u2014New molecular targets for sensitizing glioma cells to alkylating anticancer drugs","volume":"6","author":"Quiros","year":"2011","journal-title":"PLoS One."},{"issue":"21","key":"2024011116354183500_CIT0029","doi-asserted-by":"crossref","first-page":"5961","DOI":"10.1158\/1078-0432.CCR-12-0039","article-title":"FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51","volume":"18","author":"Zhang","year":"2012","journal-title":"Clin Cancer Res."},{"issue":"14","key":"2024011116354183500_CIT0030","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.3390\/ijms21144910","article-title":"Targeting the DNA damage response to overcome cancer drug resistance in glioblastoma","volume":"21","author":"Ferri","year":"2020","journal-title":"Int J Mol Sci ."},{"issue":"20","key":"2024011116354183500_CIT0031","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1007\/s00018-014-1666-4","article-title":"Functional interplay between ATM\/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress","volume":"71","author":"Yan","year":"2014","journal-title":"Cell Mol Life Sci."},{"issue":"Suppl 1","key":"2024011116354183500_CIT0032","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0140-6736(15)60373-7","article-title":"Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway","volume":"385","author":"Kwok","year":"2015","journal-title":"Lancet."},{"issue":"5","key":"2024011116354183500_CIT0033","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","journal-title":"Blood."},{"issue":"17","key":"2024011116354183500_CIT0034","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1158\/0008-5472.CAN-18-3394","article-title":"Temozolomide sensitizes MGMT-deficient tumor cells to ATR inhibitors","volume":"79","author":"Jackson","year":"2019","journal-title":"Cancer Res."},{"key":"2024011116354183500_CIT0035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","article-title":"The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer","volume":"108","author":"Smith","year":"2010","journal-title":"Adv Cancer Res."},{"issue":"1","key":"2024011116354183500_CIT0036","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1158\/0008-5472.CAN-18-1733","article-title":"Temozolomide induces senescence and repression of DNA repair pathways in glioblastoma cells via activation of ATR-CHK1, p21, and NF-\u03baB","volume":"79","author":"Aasland","year":"2019","journal-title":"Cancer Res."},{"issue":"3","key":"2024011116354183500_CIT0037","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11523-015-0397-2","article-title":"Dose-dense temozolomide in patients with MGMT-silenced chemorefractory colorectal cancer","volume":"11","author":"Pietrantonio","year":"2016","journal-title":"Target Oncol"},{"issue":"6","key":"2024011116354183500_CIT0038","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1158\/1078-0432.CCR-19-2549","article-title":"EGFR amplification induces increased DNA damage response and renders selective sensitivity to talazoparib (PARP inhibitor) in glioblastoma","volume":"26","author":"Wu","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"9","key":"2024011116354183500_CIT0039","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1073\/pnas.0830918100","article-title":"Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses","volume":"100","author":"Rothkamm","year":"2003","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2024011116354183500_CIT0040","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.dnarep.2014.03.021","article-title":"Protein ADP-ribosylation and the cellular response to DNA strand breaks","volume":"19","author":"Caldecott","year":"2014","journal-title":"DNA Repair (Amst)."},{"issue":"15","key":"2024011116354183500_CIT0041","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1091\/mbc.e16-01-0032","article-title":"Hyperactivation of ATM upon DNA-PKcs inhibition modulates p53 dynamics and cell fate in response to DNA damage","volume":"27","author":"Finzel","year":"2016","journal-title":"Mol Biol Cell."},{"issue":"10","key":"2024011116354183500_CIT0042","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med."},{"issue":"4","key":"2024011116354183500_CIT0043","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1021\/bi9518205","article-title":"Ubiquitination-dependent proteolysis of O6-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea","volume":"35","author":"Srivenugopal","year":"1996","journal-title":"Biochemistry."},{"issue":"4","key":"2024011116354183500_CIT0044","first-page":"793","article-title":"Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia","volume":"59","author":"Esteller","year":"1999","journal-title":"Cancer Res."},{"issue":"2","key":"2024011116354183500_CIT0045","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.lungcan.2014.08.007","article-title":"Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase","volume":"86","author":"Zauderer","year":"2014","journal-title":"Lung Cancer."},{"issue":"4","key":"2024011116354183500_CIT0046","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-11-2059","article-title":"Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker","volume":"18","author":"Pietanza","year":"2012","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2024011116354183500_CIT0047","doi-asserted-by":"crossref","first-page":"djv369","DOI":"10.1093\/jnci\/djv369","article-title":"Delineation of MGMT hypermethylation as a biomarker for veliparib-mediated temozolomide-sensitizing therapy of glioblastoma","volume":"108","author":"Gupta","year":"2016","journal-title":"J Natl Cancer Inst."},{"issue":"1","key":"2024011116354183500_CIT0048","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1038\/s41598-022-09614-x","article-title":"Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma","volume":"12","author":"Ganesa","year":"2022","journal-title":"Sci Rep."},{"issue":"35","key":"2024011116354183500_CIT0049","doi-asserted-by":"crossref","first-page":"5881","DOI":"10.1200\/JCO.2009.24.1034","article-title":"MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951","volume":"27","author":"van den Bent","year":"2009","journal-title":"J Clin Oncol."},{"issue":"2","key":"2024011116354183500_CIT0050","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.canlet.2010.04.013","article-title":"miR-195, miR-455-3p and miR-10a(*) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells","volume":"296","author":"Ujifuku","year":"2010","journal-title":"Cancer Lett."},{"issue":"4","key":"2024011116354183500_CIT0051","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00280-007-0520-x","article-title":"A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation","volume":"61","author":"Natsume","year":"2008","journal-title":"Cancer Chemother Pharmacol."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdad165\/54640591\/vdad165.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/6\/1\/vdad165\/55451215\/vdad165.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/6\/1\/vdad165\/55451215\/vdad165.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T23:13:26Z","timestamp":1730848406000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdad165\/7479508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdad165","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2023,12,19]]},"article-number":"vdad165"}}